Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine® Personalized Adult Stem Cell Therapy
Commercial Stage Regenerative Medicine Company Expands it s Hold Ready to Commercialize Autologous Bone Marrow Procedures
News provided by
Share this article
Share this article
PHOENIX, March 4, 2021 /PRNewswire/ (OTC - CELZ) Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation perispinal injection of bone marrow cells in patients with disc degenerative disease. Evaluation of patients at 30,60 90, 180, and 360 days revealed significant improvement in mobility and reduction in pain score . The mean pain changed from 8.9 at baseline to 4.3 at 30 days and sustained to 1.8 at 6 months and 1.3 at 12 months with a gradual reduction in overall pain medication utilization g
Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz® Regenerative Immunotherapy
Clinical Stage Cellular Therapy Company Advances Product Pipeline into Kidney Failure Market
News provided by
Share this article
Share this article
PHOENIX, Jan. 27, 2021 /PRNewswire/ (OTC-CELZ) Creative Medical Technology Holdings announced today filing of a patent application disclosing new data in which the ImmCelz® Regenerative Immunotherapy product reduced/reversed kidney failure in an animal model. Using the classical ischemia/reperfusion system, collaborators of the Company demonstrated significant reduction in markers of kidney injury at multiple timepoints after kidneys were clamped to replicate renal injury.